Versant Capital Management, Inc Allakos Inc. Transaction History

Versant Capital Management, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 29, 2022	SELL	$5.08 - $9.81 $142 - $274	-28 Reduced 58.33%	20 $0
Q3 2021 Oct 29, 2021	BUY	$76.53 - $110.43 $1,760 - $2,539	23 Added 92.0%	48 $5,000
Q2 2021 Jul 22, 2021	BUY	$85.37 - $114.1 $1,707 - $2,282	20 Added 400.0%	25 $2,000
Q2 2020 Jul 16, 2020	SELL	$44.04 - $80.69 $396 - $726	-9 Reduced 64.29%	5 $0
Q1 2020 Apr 17, 2020	SELL	$44.49 - $93.39 $6,406 - $13,448	-144 Reduced 91.14%	14 $0
Q4 2019 Jan 28, 2020	BUY	$66.49 - $137.73 $10,505 - $21,761	158 New	158 $15,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Versant Capital Management, Inc with notifications on news.